**Appendix Table D14. Reduction in frequency of migraine attack by at least 50% from baseline with divalproex sodium vs. placebo in children (results from randomized controlled clinical trial with low risk of bias)5**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Drug**  **Dose** | **Definition of the outcome** | **Events/randomized with drug** | **Events/randomized with placebo** | **Relative risk**  **(95% CI)** | **Absolute risk difference (95% CI)** |
| Divalproex sodium 250mg once daily | ≥50% reduction in 4 week migraine rate | 33/83 | 33/73 | 0.9 (0.6 to 1.3) | -0.05 (-0.21 to 0.10) |
| Divalproex sodium 500mg once daily. For the first 2 weeks dose was 250mg/day | ≥50% reduction in 4 week migraine headache rate | 27/74 | 33/73 | 0.8 (0.5 to 1.2) | -0.09 (-0.25 to 0.07) |
| Divalproex sodium 1000 mg once daily. For the first 2 weeks dose was 500 mg/day | ≥50% reduction in 4 week migraine headache rate | 37/75 | 33/73 | 1.1 (0.8 to 1.5) | 0.04 (-0.12 to 0.20) |